+ (480) 555-0103
im
1234 North Avenue Luke Lane
Follow us :
button
button
Sign in
Sign Up
button
imgi_8_liposomal

Scientific Validation of Liposomal Formulations

At OZABIO®, every liposomal formulation undergoes a comprehensive scientific evaluation, including physicochemical characterization, in-vitro studies, preclinical safety assessments, and human-based performance studies. Our validation approach emphasizes the assessment of encapsulation efficiency, vesicle stability, particle size distribution, zeta potential, and controlled release behavior to ensure superior bioavailability. We also conduct permeability evaluations and comparative performance analysis against conventional delivery systems to demonstrate enhanced absorption. Stability and compatibility studies under diverse environmental conditions further ensure product reliability throughout shelf life. All validation activities are aligned with established scientific principles and globally recognized quality standards, supporting the safety and efficacy of our liposomal formulations.

Studies

Microscopy (SEM, tEM)

Zeta Potential

Dynamic Light Scattering (DLS)

Caco-2 Study

Animal Study

Human Study

Facebook Instagram Linkedin

1.TEM-Based Structural Analysis of Liposomal Formulations

Transmission Electron Microscopy (TEM) provides high-resolution visualization of liposomal morphology, enabling assessment of vesicle size, shape, and internal structure. Liposomes generally appear as well-defined spherical vesicles with a distinct bilayer and a darker core region.
For example – Lipoza®-Q10

2.SEM-Based Surface Characterization of Liposomes

Scanning Electron Microscopy (SEM) offers detailed visualization of surface morphology, enabling assessment of particle texture, external structure, and overall physical characteristics of liposomal powders. This technique helps confirm uniformity, surface smoothness, and morphological integrity of the formulation.
For example – Lipoza®-Fe

Zeta Potential Analysis for surface charge and stability

Zeta potential analysis provides insight into the surface charge and colloidal stability of liposomal formulations, where higher negative values indicate improved dispersion stability and reduced risk of particle aggregation.
For example – Lipoza®-VitC

Dynamic Light Scattering (DLS) for particle size measurement

Dynamic Light Scattering (DLS) is employed to evaluate the particle size distribution and polydispersity of liposomal formulations, providing essential information on colloidal stability, dispersion uniformity, and potential bioavailability.
For example – Lipoza®-Curcumin

Caco-2 Study

Caco-2 studies utilize human intestinal epithelial cell monolayers to evaluate the permeability and predicted absorption of test substances across the gut barrier.
For example – Lipoza®-Glutathione
Demonstrated superior permeability, showing 0.95% transport compared to 0.29% for Reduced L-Glutathione—an approximate 3.28-fold increase. This enhanced permeability, despite lower glutathione content, indicates improved intestinal absorption and supports its potential as a more bioavailable form of glutathione supplementation.

Animal Study

Animal studies using validated animal models are essential to understand the pharmacokinetics, absorption behavior, distribution, metabolism, and safety of liposomal formulations under physiological conditions. As liposomes modify the delivery and release of active ingredients compared to conventional forms, these preclinical evaluations provide critical evidence of enhanced bioavailability and improved systemic performance, ensuring suitability for further clinical development.
For Example: Lipoza®-Ca
Pharmacokinetic results showed that Lipoza-Ca achieved a higher Cmax (36.5 µg/dL) than Tricalcium Phosphate (30.2 µg/dL), along with a greater AUC0–t (149.55 vs. 95.43 µg·dL⁻¹·h). This demonstrates improved absorption and superior bioavailability of the liposomal formulation.

Human Study

Human studies are essential to evaluate the clinical safety, pharmacokinetics, and therapeutic efficacy of liposomal formulations in humans, ensuring that the improved delivery and bioavailability observed in preclinical models is accurately translated to human physiology.
For example – Lipoza®-Fe
A single-dose bioavailability study in healthy subjects demonstrated that Lipoza-Fe resulted in significantly higher mean serum iron levels compared to Ferric Pyrophosphate, both with and without baseline correction. This outcome clearly indicates improved absorption, enhanced systemic availability, and a superior pharmacokinetic profile for the liposomal formulation.

Absorption and permeability through models like Caco-2 cell lines.

Caco-2 studies utilize human intestinal epithelial cell monolayers to evaluate the permeability and predicted absorption of test substances across the gut barrier.

For example – Lipoza-Glutathione
Demonstrated superior permeability, showing 0.95% transport compared to 0.29% for Reduced L-Glutathione—an approximate 3.28-fold increase. This enhanced permeability, despite lower glutathione content, indicates improved intestinal absorption and supports its potential as a more bioavailable form of glutathione supplementation.

ozabio
Contact Form

Contact Information

Fill out the form below and we'll get back to you soon

✓ Form submitted successfully! We'll contact you soon.
✗ There was an error submitting the form. Please try again.

* indicates required question